Catalyst Wire Dossier Catalyst Wire Dossier

VYVGART

EFGARTIGIMOD ALFA · argenx US
Drug timelines are a Plus or Pro feature.

32 regulatory and trial events tracked for VYVGART, covering 2021-12-17 to 2026-04-23. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy [Phase 3]

See pricing